Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 108 Stomach Neoplasms 68 Pancreatic Neoplasms 33 Neoplasms 24 Lymphoma, Large B-Cell, Diffuse 22 Carcinoma, Non-Small-Cell Lung 21 Neoplasm Metastasis 18 Rectal Neoplasms 17 Colonic Neoplasms 17 Esophageal Neoplasms 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Adenocarcinoma 13 Carcinoma, Hepatocellular 12 Ovarian Neoplasms 10 Biliary Tract Neoplasms 9 Adenocarcinoma Of Esophagus 9 Esophageal Squamous Cell Carcinoma 8 Cholangiocarcinoma 8 Gastrointestinal Neoplasms 7 Lymphoma, Non-Hodgkin 6 Endometrial Neoplasms 6 Gallbladder Neoplasms 5 Advanced Solid Tumors 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Carcinoma, Pancreatic Ductal 4 Breast Neoplasms 4 Advanced Solid Tumor 4 Solid Tumors 3

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Oxaliplatin × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡